1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Macular Degeneration Global Clinical Trials Review, H1, 2015

Macular Degeneration Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Macular Degeneration Global Clinical Trials Review, H1, 2015" provides an overview of Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Macular Degeneration Global Clinical Trials Review, H1, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Macular Degeneration 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Macular Degeneration to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Macular Degeneration to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Macular Degeneration 25
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Macular Degeneration Therapeutics Clinical Trials 36
Prominent Drugs 37
Latest Clinical Trials News on Macular Degeneration 38
Apr 30, 2015: Ocata Therapeutics Announces Positive Results in Treating Macular Degeneration Using Fully Differentiated Stem Cell-Derived Retinal Pigment Epithelium Cells in Asian Patients 38
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Novartis AG 39
Clinical Trial Overview of Novartis AG 39
F. Hoffmann-La Roche Ltd. 47
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 47
Bayer AG 51
Clinical Trial Overview of Bayer AG 51
Pfizer Inc. 54
Clinical Trial Overview of Pfizer Inc. 54
Regeneron Pharmaceuticals, Inc. 57
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 57
Ophthotech Corp. 59
Clinical Trial Overview of Ophthotech Corp. 59
Actavis plc 61
Clinical Trial Overview of Actavis plc 61
QLT Inc. 62
Clinical Trial Overview of QLT Inc. 62
GlaxoSmithKline Plc 63
Clinical Trial Overview of GlaxoSmithKline Plc 63
Eyetech Pharmaceuticals, Inc. 64
Clinical Trial Overview of Eyetech Pharmaceuticals, Inc. 64
Clinical Trial Overview of Top Institutes / Government 65
National Eye Institute 65
Clinical Trial Overview of National Eye Institute 65
Medical University of Vienna 67
Clinical Trial Overview of Medical University of Vienna 67
King's College Hospital NHS Foundation Trust 68
Clinical Trial Overview of King's College Hospital NHS Foundation Trust 68
Manhattan Eye Ear and Throat Hospital 69
Clinical Trial Overview of Manhattan Eye Ear and Throat Hospital 69
Vitreous-Retina-Macula Consultants of New York 70
Clinical Trial Overview of Vitreous-Retina-Macula Consultants of New York 70
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 71
Clinical Trial Overview of Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi 71
Kagawa University 72
Clinical Trial Overview of Kagawa University 72
Lawson Health Research Institute 73
Clinical Trial Overview of Lawson Health Research Institute 73
Nagoya City University 74
Clinical Trial Overview of Nagoya City University 74
The Johns Hopkins University 75
Clinical Trial Overview of The Johns Hopkins University 75
Five Key Clinical Profiles 76
Appendix 113
Abbreviations 113
Definitions 113
Research Methodology 114
Secondary Research 114
About GlobalData 115
Contact Us 115
Disclaimer 115
Source 115

List of Tables
Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2015* 7
Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 14
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 15
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2015* 18
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Macular Degeneration Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Macular Degeneration Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Macular Degeneration Therapeutics, Global, Terminated Clinical Trials, 2015* 28
Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 33
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 34
Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 35
Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 36
Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 37
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 39
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 47
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2015* 51
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 54
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2015* 57
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Ophthotech Corp., 2015* 59
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2015* 61
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by QLT Inc., 2015* 62
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline Plc, 2015* 63
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Eyetech Pharmaceuticals, Inc., 2015* 64
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2015* 65
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2015* 67
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by King's College Hospital NHS Foundation Trust, 2015* 68
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Manhattan Eye Ear and Throat Hospital, 2015* 69
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Vitreous-Retina-Macula Consultants of New York, 2015* 70
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, 2015* 71
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Kagawa University, 2015* 72
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Lawson Health Research Institute, 2015* 73
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagoya City University, 2015* 74
Macular Degeneration Therapeutics Clinical Trials Market, Global, Clinical Trials by The Johns Hopkins University, 2015* 75

List of Figures
Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 14
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2015* 15
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2015* 18
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 33
Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 34
Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 35
Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 36
Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 37
GlobalData Methodology 114

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period Summary Ophthalmology is a therapy area that deals with the diagnosis, ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.